Aptorum Group (APM) Competitors $2.33 -0.32 (-11.93%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock APM vs. PHGE, MIRA, TENX, CASI, CVKD, MDCX, RNTX, TRIB, RVPH, and FBLGShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include BiomX (PHGE), MIRA Pharmaceuticals (MIRA), Tenax Therapeutics (TENX), CASI Pharmaceuticals (CASI), Cadrenal Therapeutics (CVKD), Medicus Pharma (MDCX), Rein Therapeutics (RNTX), Trinity Biotech (TRIB), Reviva Pharmaceuticals (RVPH), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Its Competitors BiomX MIRA Pharmaceuticals Tenax Therapeutics CASI Pharmaceuticals Cadrenal Therapeutics Medicus Pharma Rein Therapeutics Trinity Biotech Reviva Pharmaceuticals FibroBiologics Aptorum Group (NASDAQ:APM) and BiomX (NYSEMKT:PHGE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Do analysts recommend APM or PHGE? BiomX has a consensus target price of $21.00, suggesting a potential upside of 3,683.78%. Given BiomX's stronger consensus rating and higher probable upside, analysts clearly believe BiomX is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BiomX 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of APM or PHGE? 3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 40.6% of BiomX shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 1.2% of BiomX shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to APM or PHGE? In the previous week, Aptorum Group had 6 more articles in the media than BiomX. MarketBeat recorded 7 mentions for Aptorum Group and 1 mentions for BiomX. Aptorum Group's average media sentiment score of 0.95 beat BiomX's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BiomX 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is APM or PHGE more profitable? Aptorum Group's return on equity of 0.00% beat BiomX's return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A BiomX N/A -127.82%-56.50% Which has more risk & volatility, APM or PHGE? Aptorum Group has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, BiomX has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Which has higher valuation and earnings, APM or PHGE? Aptorum Group has higher revenue and earnings than BiomX. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K28.93-$4.27MN/AN/ABiomXN/AN/A-$28.32M-$1.36-0.41 SummaryAptorum Group beats BiomX on 7 of the 12 factors compared between the two stocks. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.39M$2.79B$5.76B$9.75BDividend YieldN/A1.67%4.40%4.10%P/E RatioN/A22.3130.8325.91Price / Sales28.93753.34469.77121.46Price / CashN/A26.0925.7828.79Price / Book1.065.569.466.03Net Income-$4.27M$31.83M$3.27B$265.29M7 Day Performance70.96%1.47%2.37%2.86%1 Month Performance28.45%1.23%3.88%1.23%1 Year Performance-25.00%7.75%30.52%19.11% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.7362 of 5 stars$2.33-11.9%N/A-14.8%$12.39M$430K0.0030Gap DownPHGEBiomX2.0586 of 5 stars$0.51-31.1%$21.00+4,025.7%+293.0%$14.81MN/A-0.70120MIRAMIRA Pharmaceuticals3.0026 of 5 stars$1.43-3.4%$17.00+1,088.8%-22.7%$27.27MN/A-2.922Analyst UpgradeTENXTenax Therapeutics1.4637 of 5 stars$5.95-1.0%$17.00+185.7%+42.2%$27.13MN/A-6.479CASICASI Pharmaceuticals3.6973 of 5 stars$2.19-3.3%$4.00+83.1%-63.4%$27.06M$28.54M-0.86180Gap DownCVKDCadrenal Therapeutics2.3563 of 5 stars$13.18+1.0%$32.00+142.9%+69.6%$27.01MN/A-1.484MDCXMedicus Pharma1.6679 of 5 stars$1.97-1.5%$23.50+1,092.9%N/A$26.73MN/A-1.47N/AAnalyst ForecastGap UpHigh Trading VolumeRNTXRein TherapeuticsN/A$1.14+0.9%N/AN/A$26.28MN/A-0.429TRIBTrinity Biotech1.4457 of 5 stars$1.41-10.2%N/A-21.5%$25.63M$61.56M-0.48480Upcoming EarningsRVPHReviva Pharmaceuticals2.669 of 5 stars$0.53+2.3%$7.17+1,249.7%-44.4%$25.49MN/A-0.825FBLGFibroBiologics2.78 of 5 stars$0.61-1.8%$13.00+2,045.2%-62.7%$25.39MN/A-1.6810Gap Up Related Companies and Tools Related Companies PHGE Competitors MIRA Competitors TENX Competitors CASI Competitors CVKD Competitors MDCX Competitors RNTX Competitors TRIB Competitors RVPH Competitors FBLG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APM) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access